Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Tamiflu (oseltamivir phosphate) is an oral antiviral medication approved in 2000 for the treatment and prevention of influenza A and B in patients aged 2 weeks and older. It works by inhibiting viral neuraminidase, reducing viral shedding and shortening illness duration. The drug is available as an oral suspension formulation, making it accessible for pediatric and adult populations.
Product is in declining phase approaching loss of exclusivity, suggesting downsizing commercial teams and shift toward generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects
A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance
A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
Worked on TAMIFLU at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Tamiflu offers experience managing a mature, declining product through LOE transition—valuable for learning defensive commercial strategies, generic competition management, and lifecycle extension tactics. Career growth is limited on this product itself, but LOE expertise is transferable to other products facing similar challenges.